Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Soft Tissue Sarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Sarcoma (608
)
Spindle Cell Sarcoma (93
)
Osteosarcoma (53
)
Leiomyosarcoma (52
)
Ewing Sarcoma (42
)
Fibrosarcoma (33
)
Rhabdomyosarcoma (29
)
Liposarcoma (23
)
Uterine Corpus Leiomyosarcoma (22
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
Sarcoma (608
)
Spindle Cell Sarcoma (93
)
Osteosarcoma (53
)
Leiomyosarcoma (52
)
Ewing Sarcoma (42
)
Fibrosarcoma (33
)
Rhabdomyosarcoma (29
)
Liposarcoma (23
)
Uterine Corpus Leiomyosarcoma (22
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
›
Associations
(395)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
KIT exon 17 mutation
Gastrointestinal Stromal Tumor
KIT exon 17 mutation
Gastrointestinal Stromal Tumor
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New C3)
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2wk
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New C3)
KIT exon 11 mutation
Gastrointestinal Stromal Tumor
KIT exon 11 mutation
Gastrointestinal Stromal Tumor
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New C3)
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2wk
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New C3)
KIT exon 18 mutation
Gastrointestinal Stromal Tumor
KIT exon 18 mutation
Gastrointestinal Stromal Tumor
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New C3)
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2wk
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New C3)
KIT positive
Gastrointestinal Stromal Tumor
KIT positive
Gastrointestinal Stromal Tumor
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
olaratumab
Sensitive: A1 - Approval
olaratumab
Sensitive
:
A1
olaratumab
Sensitive: A1 - Approval
olaratumab
Sensitive
:
A1
No biomarker
Gastrointestinal Stromal Tumor
No biomarker
Gastrointestinal Stromal Tumor
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Liposarcoma
No biomarker
Liposarcoma
eribulin mesylate
Sensitive: A1 - Approval
eribulin mesylate
Sensitive
:
A1
eribulin mesylate
Sensitive: A1 - Approval
eribulin mesylate
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
pazopanib
Sensitive: A1 - Approval
pazopanib
Sensitive
:
A1
pazopanib
Sensitive: A1 - Approval
pazopanib
Sensitive
:
A1
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Liposarcoma
No biomarker
Liposarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Gastrointestinal Stromal Tumor
No biomarker
Gastrointestinal Stromal Tumor
ripretinib
Sensitive: A1 - Approval
ripretinib
Sensitive
:
A1
ripretinib
Sensitive: A1 - Approval
ripretinib
Sensitive
:
A1
PDGFRA exon 18 mutation
Gastrointestinal Stromal Tumor
PDGFRA exon 18 mutation
Gastrointestinal Stromal Tumor
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Fibrosarcoma
No biomarker
Fibrosarcoma
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
No biomarker
Kaposi Sarcoma
No biomarker
Kaposi Sarcoma
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Kaposi Sarcoma
No biomarker
Kaposi Sarcoma
pomalidomide
Sensitive: A1 - Approval
pomalidomide
Sensitive
:
A1
pomalidomide
Sensitive: A1 - Approval
pomalidomide
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Gastrointestinal Stromal Tumor
No biomarker
Gastrointestinal Stromal Tumor
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
KIT expression
Gastrointestinal Stromal Tumor
KIT expression
Gastrointestinal Stromal Tumor
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
C1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
C1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
ifosfamide + epirubicin + mesna
Sensitive: A2 - Guideline
ifosfamide + epirubicin + mesna
Sensitive
:
A2
ifosfamide + epirubicin + mesna
Sensitive: A2 - Guideline
ifosfamide + epirubicin + mesna
Sensitive
:
A2
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
AIM
Sensitive: A2 - Guideline
AIM
Sensitive
:
A2
AIM
Sensitive: A2 - Guideline
AIM
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
NTRK3 fusion
Soft Tissue Sarcoma
NTRK3 fusion
Soft Tissue Sarcoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
GT
Sensitive: A2 - Guideline
GT
Sensitive
:
A2
GT
Sensitive: A2 - Guideline
GT
Sensitive
:
A2
NTRK2 fusion
Gastrointestinal Stromal Tumor
NTRK2 fusion
Gastrointestinal Stromal Tumor
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Gastrointestinal Stromal Tumor
NTRK1 fusion
Gastrointestinal Stromal Tumor
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Gastrointestinal Stromal Tumor
NTRK3 fusion
Gastrointestinal Stromal Tumor
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Uterine Corpus Leiomyosarcoma
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
VAC
Sensitive: A2 - Guideline
VAC
Sensitive
:
A2
VAC
Sensitive: A2 - Guideline
VAC
Sensitive
:
A2
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
NTRK3 fusion
Gastrointestinal Stromal Tumor
NTRK3 fusion
Gastrointestinal Stromal Tumor
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login